Compare Neurocrine Biosciences Inc (NBIX) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Shell PLC — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Shell PLC trades at $100.18 (market cap $284.34B). The key difference: Shell PLC is far larger — about 19.8× Neurocrine Biosciences Inc's market cap, and Shell PLC pays a 3.12% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Shell PLC for 90 Days on average.
| NBIX | SHEL | |
|---|---|---|
Market Cap | $14.36B | $284.34B |
Volume | 1,237,180 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $185.50 | $100.20 |
52-Week Low | $123.10 | $70.31 |
Typical Hold Time | 23 Days | 90 Days |
Enterprise Value | $14.37B | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Shell (SHEL) trades at $100.2, up 3.46% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats in Q1 and Q2 2026. Fundamentally, the company maintains solid profitability with an 8.76% net margin and attractive valuation multiples, including a P/E of 11.08. Recent news highlights strategic expansions in LNG capacity and carbon capture projects, reinforcing long-term growth prospects.
The outlook for SHEL is positive, supported by analyst consensus favoring Buy ratings and a $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, while risks involve energy price volatility and execution of large-scale projects. The stock presents a balanced risk-reward profile for investors seeking exposure to energy transition themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
